In conclusion, this study demonstrates that RAD51 protein expression offers a valuable tool for predicting chemotherapy sensitivity, platinum resistance recurrence, and survival outcomes in patients with advanced epithelial ovarian cancer. Here, RAD51 is linked to ovarian carcinoma.